Publicaciones en colaboración con investigadores/as de Universidad de Navarra (22)

2020

  1. Design and implementation of a teaching project for the formation of medical identity in medical students

    Educacion Medica, Vol. 21, Núm. 3, pp. 207-211

2018

  1. Emotions and scope effects in the monetary valuation of health

    European Journal of Health Economics, Vol. 19, Núm. 3, pp. 315-325

2017

  1. Adverse events from systemic treatment of cancer and patient-reported quality of life

    Journal of Community and Supportive Oncology, Vol. 15, Núm. 5, pp. e256-e262

  2. Age effects in mortality risk valuation

    European Journal of Health Economics, Vol. 18, Núm. 7, pp. 921-932

  3. Exploring Differences between TTO and DCE in the Valuation of Health States

    Medical Decision Making, Vol. 37, Núm. 3, pp. 273-284

  4. Improving scope sensitivity in contingent valuation: Joint and separate evaluation of health states

    Health Economics (United Kingdom), Vol. 26, Núm. 12, pp. e304-e318

  5. Risk attitudes in medical decisions for others: An experimental approach

    Health Economics (United Kingdom), Vol. 26, pp. 97-113

2016

  1. An elicitation of utility for quality of life under prospect theory

    Journal of Health Economics, Vol. 48, pp. 121-134

  2. Does the Introduction of the Ranking Task in Valuation Studies Improve Data Quality and Reduce Inconsistencies? The Case of the EQ-5D-5L

    Value in Health, Vol. 19, Núm. 4, pp. 478-486

  3. Role of histological regression grade after two neoadjuvant approaches with or without radiotherapy in locally advanced gastric cancer

    British Journal of Cancer, Vol. 115, Núm. 6, pp. 655-663

2012

  1. Four-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: A validation phase II trial

    International Journal of Radiation Oncology Biology Physics, Vol. 83, Núm. 2, pp. 587-593

2011

  1. Patterns of response after preoperative intensity-modulated radiation therapy and capecitabine/oxaliplatin in rectal cancer: Is there still a place for ecoendoscopic ultrasound?

    International Journal of Radiation Oncology Biology Physics, Vol. 81, Núm. 2, pp. 439-444

  2. Patterns of response after preoperative treatment in gastric cancer

    International Journal of Radiation Oncology Biology Physics, Vol. 80, Núm. 3, pp. 698-704

2010

  1. Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model

    BMC Cancer, Vol. 10

  2. Updating controversies on the multidisciplinary management of gastric cancer

    Clinical and Translational Oncology, Vol. 12, Núm. 10, pp. 677-685

2009

  1. The novel Akt inhibitor Palomid 529 (P529) enhances the effect of radiotherapy in prostate cancer

    British Journal of Cancer, Vol. 100, Núm. 6, pp. 932-940

  2. microRNA-451 regulates macrophage migration inhibitory factor production and proliferation of gastrointestinal cancer cells

    Clinical Cancer Research, Vol. 15, Núm. 7, pp. 2281-2290

2008

  1. Phase I-II Trial of Concurrent Capecitabine and Oxaliplatin With Preoperative Intensity-Modulated Radiotherapy in Patients With Locally Advanced Rectal Cancer

    International Journal of Radiation Oncology Biology Physics, Vol. 71, Núm. 3, pp. 748-755

2007

  1. Detecting changes in tumor hypoxia with carbonic anhydrase IX and pimonidazole

    Cancer Biology and Therapy, Vol. 6, Núm. 1, pp. 70-75

  2. Rectal cancer treatment: Improving the picture

    World Journal of Gastroenterology, Vol. 13, Núm. 44, pp. 5805-5812